1. [COVID-19-associated multisystem inflammatory syndrome in children: case series at a pediatric hospital in Peru].
- Author
-
Coll-Vela LE, Zamudio-Aquise MK, Nuñez-Paucar H, Bernal-Mancilla RR, Schult-Montoya SC, Ccorahua-De La Paz M, Huby-Muñoz CL, Castillo-Torres CF, Candela-Herrera JL, Aranda-Paniora F, and Rojas-Galarza RA
- Subjects
- Adrenal Cortex Hormones administration & dosage, Antibodies, Viral analysis, COVID-19 blood, Child, Child, Preschool, Female, Hospitals, Pediatric, Humans, Immunoglobulin G analysis, Immunoglobulin M analysis, Immunoglobulins, Intravenous administration & dosage, Immunologic Factors administration & dosage, Infant, Macrophage Activation Syndrome diagnosis, Male, Peru, Systemic Inflammatory Response Syndrome blood, Systemic Inflammatory Response Syndrome drug therapy, Treatment Outcome, COVID-19 Drug Treatment, COVID-19 diagnosis, Mucocutaneous Lymph Node Syndrome diagnosis, SARS-CoV-2 immunology, Systemic Inflammatory Response Syndrome diagnosis
- Abstract
During the COVID-19 pandemic, a new, severe and unusual condition called Multisystem Inflammatory Syndrome in children emerged, from which there is still much to learn. We report 8 children admitted to Instituto Nacional de Salud del Niño, in Lima, Perú. Their mean age was 5,1 years. Their clinical presentation included fever, acute gastrointestinal symptoms, ocular and mucocutaneous involvement. Four patients met criteria for classic Kawasaki Disease. All the patients had positive serology for SARS-CoV-2, abnormal complete blood counts and coagulation tests, and elevated inflammatory markers. Five had elevated liver enzymes and three had kidney involvement. Four patients met criteria for Macrophage Activation Syndrome. All of them received intravenous immune globulin, corticosteroids and aspirin. No coronary aneurysms were identified. Only one developed miocarditis, shock and was admitted to the Pediatric Intensive Care Unit. Most patients recovered successfully. Every child with fever, gastrointestinal and dermatological symptoms, associated with prior exposure to SARS-CoV-2, should be investigated for multi-systemic compromise.
- Published
- 2020
- Full Text
- View/download PDF